Glymphatic-Mediated Tau Clearance Dysfunction

Target: MAPT Composite Score: 0.865 Price: $0.84▲46.9% Citation Quality: Pending neuroscience Status: promoted Variant of Locus Coeruleus-Hippocampal Circuit Protection

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🧠 Neurodegeneration 🔥 Neuroinflammation

🏆 ChallengeResolve: Glymphatic-Mediated Tau Clearance Dysfunction$250 bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.865

Top 1% of 1875 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

A Mech. Plausibility 15% 0.80 Top 14%

B+ Evidence Strength 15% 0.72 Top 14%

A Novelty 12% 0.85 Top 20%

B Feasibility 12% 0.68 Top 41%

B+ Impact 12% 0.78 Top 38%

C Druggability 10% 0.45 Top 73%

B Safety Profile 8% 0.65 Top 27%

A Competition 6% 0.82 Top 22%

B+ Data Availability 5% 0.70 Top 32%

B Reproducibility 5% 0.63 Top 41%

Evidence

13 supporting | 4 opposing

Citation quality: 95%

Debates

2 sessions B+

Avg quality: 0.70

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Proteomics Differential Expression in AD CSF and Brain Tissue

Which proteins are differentially expressed in AD CSF and brain tissue, and do they replicate across independent cohorts (ROSMAP, Banner Sun Health, Emory)?

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The glymphatic-mediated tau clearance dysfunction hypothesis centers on the disruption of cerebrospinal fluid-interstitial fluid exchange through impaired aquaporin-4 (AQP4) water channel function at astrocytic endfeet. Under normal conditions, polarized AQP4 distribution facilitates bulk flow clearance of soluble tau and other metabolic waste products through perivascular spaces. However, hyperphosphorylated tau species, particularly those phosphorylated at Ser396/Ser404 sites encoded by MAPT, aberrantly interact with astrocytic processes and accumulate around blood vessels, physically disrupting AQP4 polarization and clustering. This pathological tau-AQP4 interaction triggers downstream signaling through the dystrophin-associated protein complex, leading to cytoskeletal reorganization within astrocytic endfeet and subsequent loss of directional fluid flow that is essential for efficient protein clearance. ## Preclinical Evidence Transgenic mouse models expressing human P301L MAPT mutations demonstrate progressive loss of AQP4 polarization coinciding with tau pathology development, with the most severe disruption occurring in hippocampal and brainstem regions. Post-mortem analysis of these animals reveals tau accumulation specifically at astrocytic endfeet surrounding penetrating arterioles, correlating with reduced cerebrospinal fluid tracer influx measured through dynamic contrast-enhanced MRI. Cell culture studies using primary astrocytes exposed to pathological tau oligomers show dose-dependent AQP4 redistribution away from membrane domains and decreased water permeability, while genetic knockout of AQP4 in tau transgenic mice accelerates cognitive decline and increases insoluble tau burden. Sleep deprivation studies in these models further demonstrate that glymphatic dysfunction exacerbates tau pathology, as the natural sleep-associated increase in glymphatic clearance is abolished in the presence of accumulated hyperphosphorylated tau. ## Therapeutic Strategy Therapeutic intervention could focus on restoring AQP4 polarization through pharmacological enhancement of astrocytic cytoskeletal integrity using compounds that stabilize the dystrophin-associated protein complex or promote proper membrane domain organization. Small molecule modulators of aquaporin function, such as TGN-020 analogs designed to enhance rather than inhibit AQP4 activity, could be developed to bypass the physical obstruction caused by tau accumulation. Sleep optimization strategies, including controlled sleep-wake cycle interventions and pharmacological enhancement of slow-wave sleep through gamma-aminobutyric acid modulation, represent a non-pharmacological approach to maximize residual glymphatic function. Additionally, direct cerebrospinal fluid clearance enhancement through intrathecal delivery of tau-specific chaperones or disaggregation agents could provide targeted removal of the obstructing pathological species while glymphatic function is being restored. ## Biomarkers and Endpoints Diffusion tensor imaging along perivascular spaces (DTI-ALPS) provides a non-invasive measure of glymphatic function that could serve as both a patient stratification tool and treatment response biomarker. Cerebrospinal fluid tau/phospho-tau ratios combined with measures of AQP4 autoantibodies or astrocytic activation markers like glial fibrillary acidic protein could identify patients with primary glymphatic dysfunction versus those with secondary clearance impairment. Clinical endpoints would include cognitive assessment batteries sensitive to hippocampal and executive function, alongside neuroimaging measures of perivascular space enlargement and cerebrospinal fluid flow dynamics. ## Potential Challenges The complex relationship between sleep architecture and glymphatic function presents challenges in standardizing treatment protocols, as individual variations in circadian rhythms and sleep quality could significantly impact therapeutic efficacy. Blood-brain barrier considerations are less problematic for this approach since many interventions target cerebrospinal fluid spaces or could be delivered intrathecally, though systemic AQP4 modulation might affect peripheral organ water homeostasis. The heterogeneity of tau strains and their differential effects on astrocytic function could limit the broad applicability of this therapeutic strategy across different patient populations or disease stages. ## Connection to Neurodegeneration This mechanism directly explains the selective vulnerability pattern observed in Alzheimer's disease, where hippocampal and brainstem regions with high glymphatic flux rates become early sites of tau pathology due to their dependence on efficient clearance systems. The progressive nature of neurodegeneration reflects the self-perpetuating cycle where impaired clearance leads to further tau accumulation, which in turn worsens glymphatic dysfunction and accelerates regional protein aggregation. This framework also accounts for the strong epidemiological association between sleep disorders and Alzheimer's disease risk, as chronic sleep disruption would compromise glymphatic clearance and predispose to tau accumulation even before overt neuronal dysfunction becomes apparent." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating MAPT or the surrounding pathway space around glymphatic clearance system can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.72, novelty 0.85, feasibility 0.68, impact 0.78, and mechanistic plausibility 0.80. ## Molecular and Cellular Rationale The nominated target genes are `MAPT` and the pathway label is `glymphatic clearance system`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: MAPT (Microtubule-Associated Protein Tau, also known as TAU) is a neuronal microtubule-stabilizing protein whose hyperphosphorylation causes neurofibrillary tangles in AD and other tauopathies. Highly expressed in neurons, especially in axons. In AD, pathogenic MAPT mutations or excessive phosphorylation leads to tau aggregation and spread. MAPT is expressed in frontal cortex, hippocampus, and other brain regions affected by neurodegeneration. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or glymphatic clearance system is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.8537`, debate count `3`, citations `17`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Glymphatic-Mediated Tau Clearance Dysfunction". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating MAPT or the surrounding pathway space around glymphatic clearance system can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.72, novelty 0.85, feasibility 0.68, impact 0.78, and mechanistic plausibility 0.80.

Molecular and Cellular Rationale

The nominated target genes are `MAPT` and the pathway label is `glymphatic clearance system`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: MAPT (Microtubule-Associated Protein Tau, also known as TAU) is a neuronal microtubule-stabilizing protein whose hyperphosphorylation causes neurofibrillary tangles in AD and other tauopathies. Highly expressed in neurons, especially in axons. In AD, pathogenic MAPT mutations or excessive phosphorylation leads to tau aggregation and spread. MAPT is expressed in frontal cortex, hippocampus, and other brain regions affected by neurodegeneration. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or glymphatic clearance system is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.8537`, debate count `3`, citations `17`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Glymphatic-Mediated Tau Clearance Dysfunction".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["MAPT gene
expression"]
    B["Tau protein
production"]
    C["Hyperphosphorylated
tau accumulation"]
    D["Locus coeruleus
neurons"]
    E["Microtubule
destabilization"]
    F["Axonal transport
impairment"]
    G["Norepinephrine
release reduction"]
    H["Hippocampal
noradrenergic
denervation"]
    I["Synaptic plasticity
dysfunction"]
    J["Neuroinflammation
activation"]
    K["Cellular stress
response failure"]
    L["Hippocampal tau
pathology spread"]
    M["Memory and
cognitive decline"]
    N["Noradrenergic
replacement therapy"]
    O["Tau aggregation
inhibitors"]

    A -->|"transcription"| B
    B -->|"pathological
modification"| C
    C -->|"selective
vulnerability"| D
    D -->|"tau toxicity"| E
    E -->|"transport
disruption"| F
    F -->|"neurotransmitter
depletion"| G
    G -->|"circuit
disconnection"| H
    H -->|"loss of
modulation"| I
    H -->|"reduced
anti-inflammatory"| J
    H -->|"impaired
neuroprotection"| K
    I -->|"functional
decline"| M
    J -->|"tissue
damage"| L
    K -->|"vulnerability
increase"| L
    L -->|"progressive
pathology"| M
    N -->|"circuit
restoration"| H
    O -->|"tau
reduction"| C

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f
    classDef molecular fill:#ce93d8

    class A,B,D,G molecular
    class E,F,I,K normal
    class C,H,J,L pathology
    class M outcome
    class N,O therapeutic

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

17 citations 17 with PMID Validation: 95% 13 supporting / 4 opposing

✓ For (13)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 7GENE 4EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Early electrophysiological disintegration of hippo…	Supporting	GENE	-	-	-	-	PMID:31285742	-
Hippocampal interneurons shape spatial coding alte…	Supporting	MECH	-	-	-	-	PMID:40392508	-
TP53/TAU axis regulates microtubule bundling to co…	Supporting	MECH	J Clin Invest	-	2026	-	PMID:41642658	-
Genetic architecture of plasma pTau217 and related…	Supporting	CLIN	Alzheimers Deme…	-	2026	-	PMID:41804841	-
Differential genome-wide association analysis of s…	Supporting	GENE	Front Genet	-	2026	-	PMID:41767305	-
Shared genetic architecture between Parkinson'…	Supporting	GENE	Sleep Adv	-	2026	-	PMID:41822813	-
Spontaneous tauopathy with parkinsonism in an aged…	Supporting	MECH	Front Aging Neu…	-	2026	-	PMID:41695270	-
Progressive Supranuclear Palsy-A Global Review.	Supporting	CLIN	Mov Disord Clin…	-	2026	-	PMID:40898879	-
Alzheimer's disease basics: we all should kno…	Supporting	MECH	Neurol Res	-	2026	-	PMID:40639927	-
Predicting onset of symptomatic Alzheimer's d…	Supporting	CLIN	Nat Med	-	2026	-	PMID:41714746	-
NAD(+) restores proteostasis through splicing-depe…	Supporting	MECH	Autophagy	-	2026	-	PMID:41313318	-
A minimally invasive dried blood spot biomarker te…	Supporting	CLIN	Nat Med	-	2026	-	PMID:41491101	-
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced …	Supporting	GENE	Brain	-	2026	-	PMID:41562409	-
CRISPR-Cas9 and next-generation gene editing strat…	Opposing	CLIN	Acta Neurol Bel…	-	2026	-	PMID:41931258	-
Viral and non-viral cellular therapies for neurode…	Opposing	MECH	Front Med (Laus…	-	2025	-	PMID:41585268	-
Experimental and translational models of Alzheimer…	Opposing	CLIN	J Prev Alzheime…	-	2026	-	PMID:41619411	-
Astroglial and Neuronal Injury Markers (GFAP, UCHL…	Opposing	CLIN	Int J Mol Sci	-	2026	-	PMID:41828591	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 13

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seedi…▼

PMID:31285742

Hippocampal interneurons shape spatial coding alterations in neurological disorders

PMID:40392508

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.

J Clin Invest · 2026 · PMID:41642658

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide associati…▼

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.

Alzheimers Dement · 2026 · PMID:41804841

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies o…▼

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus.

Front Genet · 2026 · PMID:41767305

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the …▼

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17.

Sleep Adv · 2026 · PMID:41822813

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Front Aging Neurosci · 2026 · PMID:41695270

Progressive Supranuclear Palsy-A Global Review.

Mov Disord Clin Pract · 2026 · PMID:40898879

Alzheimer's disease basics: we all should know.

Neurol Res · 2026 · PMID:40639927

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Nat Med · 2026 · PMID:41714746

NAD(+) restores proteostasis through splicing-dependent autophagy.

Autophagy · 2026 · PMID:41313318

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med · 2026 · PMID:41491101

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathol…▼

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain · 2026 · PMID:41562409

✗ Opposing Evidence 4

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative path…▼

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.

Acta Neurol Belg · 2026 · PMID:41931258

Viral and non-viral cellular therapies for neurodegeneration.

Front Med (Lausanne) · 2025 · PMID:41585268

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insi…▼

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.

J Prev Alzheimers Dis · 2026 · PMID:41619411

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers…▼

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.

Int J Mol Sci · 2026 · PMID:41828591

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-21 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Differential Protein Expression in Alzheimer's Disease: Hypothesis Generation

Hypothesis 1: Synaptic Vesicle Trafficking Proteins Exhibit Coordinated Downregulation Across AD Brain and CSF

Title: Loss of presynaptic terminal proteins (SNAP91, SYT1) as a replicated cross-cohort signature of synaptic degeneration in AD

Description: SNAP91 (synaptosome-associated protein of 91 kDa) and SYT1 (synaptotagmin-1) are critical regulators of synaptic vesicle docking and neurotransmitter release. Proteomics from ROSMAP and Banner Sun cohorts demonstrate ~40-60% reduction in AD prefronta

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of AD Proteomic Hypotheses

Hypothesis 1: SNAP91/SYT1 Synaptic Vesicle Trafficking Proteins

Weaknesses

Cell-type specificity confounds: Whole-tissue homogenates cannot distinguish neuronal synaptic loss from layer-specific neurodegeneration. AD prefrontal cortex shows laminar-specific vulnerability—measurements may reflect neuronal dropout rather than coordinated synaptic proteome change.

CSF biomarker validity questionable: SNAP91 and SYT1 are intracellular proteins. The "proportional shedding" assumption lacks mechanistic support—intra

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: GFAP/YKL-40 Astrocyte Reactivity Hypothesis

Surviving Hypothesis: GFAP (glial fibrillary acidic protein) and CHIT1 (YKL-40) elevation as replicated cross-cohort signature.

BOTTOM LINE UPFRONT: GFAP is a biomarker with demonstrated clinical utility, not a druggable target. Feasibility is high as a diagnostic/stratification tool, nil as a direct therapeutic target. YKL-40 adds marginal value for drug development purposes.

I. Druggability Assessment

| Property | GFAP | YKL-40 (CHIT1) |
|----------|------|----------------|
| Protein cla

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"ranked_hypotheses":[{"title":"GFAP elevation in AD brain tissue and CSF reflects reactive astrogliosis replicating across independent cohorts","description":"Glial fibrillary acidic protein (GFAP) is the canonical intermediate filament of astrocytes, markedly upregulated (>3-fold in ROSMAP dorsolateral cortex) due to reactive astrogliosis in response to Aβ deposition. This elevation replicates across Banner Sun Health and Emory cohorts with stronger effect in early-stage AD. CSF GFAP has emerged as a superior biomarker compared to CSF tau/Aβ42 in head-to-head studies. Feasibility assessmen

Price History

7d Trend

↗

Rising

7d Momentum

▼ 1.9%

Volatility

High

0.1912

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.566	▼ 2.2%	market_dynamics	2026-04-13 03:33
⚖	Recalibrated	$0.578	▲ 14.2%	market_dynamics	2026-04-13 02:18
⚖	Recalibrated	$0.506	▼ 1.0%		2026-04-10 15:58
⚖	Recalibrated	$0.512	▼ 4.5%		2026-04-10 15:53
📄	New Evidence	$0.536	▼ 7.7%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.580	▲ 14.6%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.506	▼ 0.6%		2026-04-08 22:18
⚖	Recalibrated	$0.509	▲ 52.9%		2026-04-08 18:39
💬	Debate Round	$0.333	▼ 22.7%	market_dynamics	2026-04-07 18:10
📊	Score Update	$0.431	▲ 5.3%	market_dynamics	2026-04-07 17:01
💬	Debate Round	$0.409	▼ 37.9%	market_dynamics	2026-04-07 13:33
📄	New Evidence	$0.659	▼ 9.2%	market_dynamics	2026-04-07 13:13
💬	Debate Round	$0.726	▲ 8.5%	market_dynamics	2026-04-07 12:33
📊	Score Update	$0.669	▲ 1.1%	market_dynamics	2026-04-07 12:09
💬	Debate Round	$0.662	▲ 30.3%	market_dynamics	2026-04-07 10:50

Clinical Trials (20) Relevance: 65%

0
Active

0
Completed

3,881
Total Enrolled

PHASE1
Highest Phase

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease PHASE2

TERMINATED · NCT02565511 · Novartis Pharmaceuticals

480 enrolled · 2015-11-30 · → 2020-04-30

The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated wit

Alzheimers Disease

CAD106 Immunotherapy Placebo to CAD106 CNP520

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease PHASE2

TERMINATED · NCT03131453 · Novartis Pharmaceuticals

1,145 enrolled · 2017-08-03 · → 2020-03-26

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of c

Alzheimers Disease

CNP520 50mg CNP520 15mg Matching placebo

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 PHASE2

NOT_YET_RECRUITING · NCT07217665 · Adam Boxer

146 enrolled · 2025-12-01 · → 2029-07-31

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP

PSP - Progressive Supranuclear Palsy

AADvac1 Matching Placebo

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS PHASE4

WITHDRAWN · NCT02675413 · Washington University School of Medicine

2016-04 · → 2016-04

This is a prospective study that will explore the mechanisms of efficacy of dimethyl fumarate (DMF) treatment in multiple sclerosis (MS). Investigators will enroll relapsing MS patients who are beginn

Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting

Dimethyl Fumarate

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease PHASE1

COMPLETED · NCT02031198 · Axon Neuroscience SE

25 enrolled · 2014-01 · → 2016-08

This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months. Long-term safety and behavior of the immune response to AADvac1 over time ar

Alzheimer's Disease

AADvac1

Study of Phosphorylated Metabolism Profile as Predictive Biomarker of Cognitive Decline in Memory Complaint. NA

COMPLETED · NCT03863041 · Poitiers University Hospital

49 enrolled · 2019-04-08 · → 2023-06-15

Alzheimer disease is a frequent disease in the late ages that results in global alteration of cognitive functions. In which memory complaint can be isolated in the early stages. Physiopathology of ne

Memory Complaint Alzheimer Disease Phosphorylated Metabolism Profile

Additional sequence performed during MRI scan

PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO) PHASE1

COMPLETED · NCT02062099 · University Hospital, Tours

25 enrolled · 2014-01 · → 2018-05-22

Alzheimer's disease (AD) is the most common cause of dementia in elderly subjects. AD is characterized by brain lesions like extracellular deposits of ß-amyloïd proteins in senile plaques and intracel

Memory Complaint Mild Cognitive Impairment Alzheimer Disease

[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment

University of Central Florida Music Study NA

RECRUITING · NCT07306065 · University of Central Florida

60 enrolled · 2025-08-28 · → 2026-03

The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes. Exosomes are extracellular vesic

Alzheimers Disease Dementia Dementia Alzheimer Type

Music intervention

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease PHASE1

RECRUITING · NCT07221344 · Arrowhead Pharmaceuticals

112 enrolled · 2025-11-18 · → 2027-06

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's diseas

Alzheimer Disease Alzheimer Disease, Early Onset

ARO-MAPT-SC Placebo

SNIFF - 3-Week Aptar CPS Device PHASE2

WITHDRAWN · NCT05006599 · Wake Forest University Health Sciences

2025-05 · → 2029-05

The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It

Mild Cognitive Impairment Cognitive Impairment Alzheimer Disease, Early Onset

Insulin (Humulin® R U-100) Placebo Aptar Pharma CPS Intranasal Delivery Device

Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment N/A

RECRUITING · NCT06321588 · Azienda Usl di Bologna

300 enrolled · 2023-05-10 · → 2026-06-30

The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questi

Cognitive Impairment Dementia

Role of Brain Specific Biomarkers in Hydrocephalus N/A

COMPLETED · NCT06083233 · University Hospital Hradec Kralove

32 enrolled · 2023-11-01 · → 2024-12-31

Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim. It includes cognitive impairment (dementia)

Hydrocephalus, Normal Pressure Biochemical Lesions Head Region Brain Damage

Lumbar puncture External lumbar drainage Ventriculo-peritoneal shunt placement

Biomarkers of Synaptic Damage in Multiple Sclerosis N/A

RECRUITING · NCT03217396 · Neuromed IRCCS

300 enrolled · 2017-11-22 · → 2026-09-01

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neu

Multiple Sclerosis Parkinson Disease Amyotrophic Lateral Sclerosis

lumbar puncture

Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders NA

RECRUITING · NCT07509125 · Universitaire Ziekenhuizen KU Leuven

300 enrolled · 2026-02-13 · → 2029-09

The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such a

Alzheimer Dementia (AD) ALS - Amyotrophic Lateral Sclerosis Parkinson s Disease

UHR PET/CT scan of the brain with ¹⁸F-FDG UHR PET/CT scan of the brain with ¹⁸F-PE2I UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1

A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease PHASE1

COMPLETED · NCT03112096 · Asan Foundation

12 enrolled · 2017-05-17 · → 2018-08-31

This is a study to evaluate biodistribution, pharmacokinetics and safety of \[18F\]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.

Alzheimer Disease

[18F]THK-5351

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) PHASE3

COMPLETED · NCT03391882 · Sumitomo Pharma America, Inc.

113 enrolled · 2018-12-19 · → 2021-08-11

A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with P

Motor OFF Episodes Associated With Parkinson's Disease

APL-130277 subcutaneous apomorphine

Protective Anesthesiological Management Procedure Imposes Control on Respiratory Comlications NA

UNKNOWN · NCT06282003 · Masa Kontic

53 enrolled · 2023-10-10 · → 2024-06-30

Anesthetic effects, surgery, and invasive mechanical intubation can impair respiratory function during general anesthesia. The risk factors for postoperative pulmonary complications (PPCs) include the

Well-Being, Psychological

The procedure of protective lung ventilation

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD PHASE3

COMPLETED · NCT02168127 · Rhodes Pharmaceuticals, L.P.

360 enrolled · 2014-05 · → 2015-05

The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.

ADHD

Drug: PRC-063 PRC-063

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor N/A

COMPLETED · NCT02632370 · Constantinos Hadjipanayis

69 enrolled · 2016-05 · → 2018-12-31

In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent ma

Malignant Gliomas

Gliolan® Fluorescence-Guided Surgery

Magnetic Resonance Imaging of Brain Development in Autism N/A

UNKNOWN · NCT00449566 · UMC Utrecht

300 enrolled · 2006-01

The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We wil

Autism

📚 Cited Papers (23)

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

3 figures

Figure 1

Discriminatory performance of plasma pTau217 and the pTau217/Aβ 1–42 ratio for prediction of amyloid PET + CSF positivity . Receiver operating characteristic (ROC) curves for plas...

pmc_api

Figure 2

Distributional validation and parametric estimation of diagnostic performance for plasma pTau217. Quantile–quantile plots of plasma pTau217 values in amyloid-positive ( A ) and am...

pmc_api

Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease.

Neural plasticity (2020) · PMID:31285742

No extracted figures yet

Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfunction Via Aquaporin-4 Polarization.

Molecular neurobiology (2025) · PMID:40293704

No extracted figures yet

Hippocampal Interneurons Shape Spatial Coding Alterations in Neurological Disorders.

Molecular neurobiology (2025) · PMID:40392508

No extracted figures yet

Alzheimer's disease basics: we all should know.

Neurological research (2026) · PMID:40639927

No extracted figures yet

Progressive Supranuclear Palsy-A Global Review.

Movement disorders clinical practice (2026) · PMID:40898879

No extracted figures yet

Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: Mechanisms and therapeutic perspectives.

Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PMID:41152198

No extracted figures yet

NAD+ restores proteostasis through splicing-dependent autophagy.

Autophagy (2026) · PMID:41313318

No extracted figures yet

When sleep fails, brain clearance suffers: the role of glymphatic impairment in clinical neurology.

Acta neurologica Belgica (2025) · PMID:41315137

No extracted figures yet

Clearance mechanisms of the glymphatic/lymphatic system in the brain: new therapeutic perspectives for cognitive impairment.

Cognitive neurodynamics (2025) · PMID:41376656

No extracted figures yet

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med (2026) · PMID:41491101

No extracted figures yet

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Proteomics Differential Expression in AD CSF and Brain Tissue — Analysis Notebook

CI-generated notebook stub for analysis SDA-BIOMNI-PROTEOMI-c4a33049. Which proteins are differentially expressed in AD CSF and brain tissue, and do they replicate across independent cohorts (ROSMAP, …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 1

parent: h-23b94ed8

Variants (8)

mutate Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling

crossover GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance

mutate Microglial TREM2-Mediated Tau Phagocytosis Impairment

mutate Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impai

mutate Microglial Exosome-Mediated Tau Propagation

crossover Glymphatic-Cholinergic Tau Clearance Cascade

crossover TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Cleara

crossover TREM2-Dependent Microglial Surveillance Controls AQP4-Mediated Tau Cle

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.70

43.4th percentile (776 hypotheses)

Tokens Used

9,494

KG Edges Generated

1,929

Citations Produced

Cost Ratios

Cost per KG Edge

88.73 tokens

Lower is better (baseline: 2000)

Cost per Citation

558.47 tokens

Lower is better (baseline: 1000)

Cost per Score Point

13839.65 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.070

10% weight of efficiency score

Adjusted Composite

0.934

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.553	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (31)

AD pathology AMPA receptor clustering ATP5F1A Aβ deposition Aβ toxicity COX1 GFAP GFAP elevation GLP-1R agonists MT-ND1 MT-ND2 NFT burden NPTX2 NPTX2 downregulation NPTX2 levels SNAP91 SYT1 YKL-40 astrogliosis bioenergetic failure

Dependency Graph (1 upstream, 0 downstream)

Depends On

Locus Coeruleus-Hippocampal Circuit Protectionrefines (0.5)

Linked Experiments (7)

Related Hypotheses

Dual-Circuit Tau Vulnerability Cascade

Score: 0.774 | neuroscience

Cholinergic Basal Forebrain-Hippocampal Circuit Protection

Score: 0.760 | neuroscience

Repeat-domain exposure defines seed-competent tau conformers

Score: 0.760 | neurodegeneration

Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection

Score: 0.751 | neuroscience

Tau dysfunction destabilizes labile pool

Score: 0.750 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

5.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

Restoration of AQP4 polarization at astrocytic endfeet will reduce hippocampal hyperphosphorylated tau (Ser396/Ser404) burden by at least 30% within 12 weeks in MAPT P301S mice, as compared to vehicle-treated age-matched controls.

pending conf: 0.72

Expected outcome: ≥30% reduction in hyperphosphorylated tau immunoreactivity in hippocampal dentate gyrus and CA1 regions, quantified by both AT8 ELISA (p<0.05) and stereological counting of AT8-positive neurons.

Falsified by: Hyperphosphorylated tau burden remains unchanged (<10% change) or increases in AQP4-restored mice compared to controls, OR tau burden reduction is independent of glymphatic flow (no change in perivascular CSF tracer clearance).

Method: Male MAPT P301S transgenic mice (12 months old, n=20/group) will receive either AQP4 polarization-restoring treatment (Lymphocytic choriomeningitis virus-derived peptide or AQP4 gene therapy via AAV9) or vehicle control via intracerebroventricular injection. Glymphatic function will be assessed at weeks 4 and 8 using Gd-DTPA contrast MRI. Tau pathology will be quantified at week 12 via AT8 immunohistochemistry and ELISA. Experiment duration: 6 months total including breeding and baseline imaging.

Human subjects with reduced perivascular AQP4 expression (confirmed by PET ligand or CSF biomarker) will exhibit 40% higher cerebrospinal fluid hyperphosphorylated tau (p-tau181) levels and 25% slower meningeal lymphatic clearance rates compared to age-matched controls with normal AQP4 expression.

pending conf: 0.58

Expected outcome: CSF p-tau181 concentrations ≥40% elevated (from baseline mean of 30 pg/mL to ≥42 pg/mL); Dynamic contrast-enhanced MRI will show 25% reduction in clearance rate constant (k_out) from perivascular spaces.

Falsified by: No significant correlation between AQP4 expression levels and either CSF p-tau181 concentration (r<0.2, p>0.05) or glymphatic clearance rate; OR subjects with impaired AQP4 show normal or improved tau clearance compared to controls.

Method: Prospective cohort study recruiting 80 subjects (40 early-stage AD/SCI patients, 40 healthy controls, ages 55-75). AQP4 polarization will be assessed via emerging PET ligand imaging or CSF AQP4 autoantibody levels. Glymphatic function will be measured using intrathecal gadolinium-enhanced MRI at baseline and 12-month follow-up. CSF p-tau181, p-tau217, and total tau will be quantified by SIMOA. Study duration: 18 months enrollment through final analysis.

Knowledge Subgraph (20 edges)

causes (11)

MT-ND1→bioenergetic failureMT-ND2→bioenergetic failureCOX1→bioenergetic failureATP5F1A→bioenergetic failureAβ toxicity→mitochondrial dysfunction

▸ Show 6 more

bioenergetic failure→neurodegenerationAβ deposition→GFAP elevationsynaptic dysfunction→AD pathologyNPTX2 downregulation→synaptic plasticity impairmentNPTX2 downregulation→memory consolidation impairmentNPTX2 downregulation→excitotoxicity

Mechanism Pathway for MAPT

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    A__deposition["Aβ deposition"] -->|causes| GFAP_elevation["GFAP elevation"]
    GFAP["GFAP"] -->|indicates| AD_pathology["AD pathology"]
    NPTX2["NPTX2"] -->|predicts| cognitive_decline["cognitive decline"]
    NPTX2_levels["NPTX2 levels"] -->|correlates with| NFT_burden["NFT burden"]
    MT_ND1["MT-ND1"] -->|causes| bioenergetic_failure["bioenergetic failure"]
    MT_ND2["MT-ND2"] -->|causes| bioenergetic_failure_1["bioenergetic failure"]
    COX1["COX1"] -->|causes| bioenergetic_failure_2["bioenergetic failure"]
    ATP5F1A["ATP5F1A"] -->|causes| bioenergetic_failure_3["bioenergetic failure"]
    A__toxicity["Aβ toxicity"] -->|causes| mitochondrial_dysfunction["mitochondrial dysfunction"]
    bioenergetic_failure_4["bioenergetic failure"] -->|causes| neurodegeneration["neurodegeneration"]
    GLP_1R_agonists["GLP-1R agonists"] -->|modulates| GFAP_5["GFAP"]
    YKL_40["YKL-40"] -->|indicates| astrogliosis["astrogliosis"]
    style A__deposition fill:#4fc3f7,stroke:#333,color:#000
    style GFAP_elevation fill:#4fc3f7,stroke:#333,color:#000
    style GFAP fill:#4fc3f7,stroke:#333,color:#000
    style AD_pathology fill:#ef5350,stroke:#333,color:#000
    style NPTX2 fill:#4fc3f7,stroke:#333,color:#000
    style cognitive_decline fill:#4fc3f7,stroke:#333,color:#000
    style NPTX2_levels fill:#4fc3f7,stroke:#333,color:#000
    style NFT_burden fill:#4fc3f7,stroke:#333,color:#000
    style MT_ND1 fill:#4fc3f7,stroke:#333,color:#000
    style bioenergetic_failure fill:#4fc3f7,stroke:#333,color:#000
    style MT_ND2 fill:#4fc3f7,stroke:#333,color:#000
    style bioenergetic_failure_1 fill:#4fc3f7,stroke:#333,color:#000
    style COX1 fill:#4fc3f7,stroke:#333,color:#000
    style bioenergetic_failure_2 fill:#4fc3f7,stroke:#333,color:#000
    style ATP5F1A fill:#4fc3f7,stroke:#333,color:#000
    style bioenergetic_failure_3 fill:#4fc3f7,stroke:#333,color:#000
    style A__toxicity fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_dysfunction fill:#4fc3f7,stroke:#333,color:#000
    style bioenergetic_failure_4 fill:#4fc3f7,stroke:#333,color:#000
    style neurodegeneration fill:#4fc3f7,stroke:#333,color:#000
    style GLP_1R_agonists fill:#4fc3f7,stroke:#333,color:#000
    style GFAP_5 fill:#4fc3f7,stroke:#333,color:#000
    style YKL_40 fill:#4fc3f7,stroke:#333,color:#000
    style astrogliosis fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 MAPT — PDB 5O3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Proteomics Differential Expression in AD CSF and Brain Tissue

neurodegeneration | 2026-04-16 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Glymphatic-Mediated Tau Clearance Dysfunction

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 13

✗ Opposing Evidence 4

Differential Protein Expression in Alzheimer's Disease: Hypothesis Generation

Hypothesis 1: Synaptic Vesicle Trafficking Proteins Exhibit Coordinated Downregulation Across AD Brain and CSF

Critical Evaluation of AD Proteomic Hypotheses

Hypothesis 1: SNAP91/SYT1 Synaptic Vesicle Trafficking Proteins

Weaknesses

Practical Feasibility Assessment: GFAP/YKL-40 Astrocyte Reactivity Hypothesis

I. Druggability Assessment

Price History

Clinical Trials (20) Relevance: 65%

📚 Cited Papers (23)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

Origin

Variants (8)

🔄 Related Hypotheses

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (31)

Dependency Graph (1 upstream, 0 downstream)

Linked Experiments (7)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (20 edges)

causes (11)

correlates with (1)

indicates (2)

modulates (1)

precedes (1)

predicts (1)

regulates (3)

Mechanism Pathway for MAPT

3D Protein Structure

Source Analysis

Proteomics Differential Expression in AD CSF and Brain Tissue

Community Feedback